oncnursingnews2 小时
Tislelizumab Plus Chemotherapy Demonstrates Strong Anti-Tumor Activity in ESCC
The phase 3 RATIONALE-306 study found no significant difference in overall survival benefits from tislelizumab plus ...
oncnursingnews21 小时
Long-Term Survival Benefit Seen With Nivolumab Plus Chemo in Chinese Patients With Advanced ...
Nivolumab plus chemotherapy improved long-term survival in Chinese patients with advanced gastric, GEJ, or esophageal cancer.
oncnursingnews19 小时
Nivolumab/Chemo Shows Lasting Benefit in Advanced Gastroesophageal Cancers
Five-year data shows lasting benefit for patients with advanced gastroesophageal cancers treated with nivolumab and chemotherapy.
oncnursingnews6 天
Adding Lenvatinib/Pembrolizumab to TACE Extends PFS in Unresectable Liver Cancer
The addition of lenvatinib/pembrolizumab to TACE showed a numerical improvement in PFS, but longer follow-up is necessary to ...
oncnursingnews4 天
Ann Culkin, RN, OCN
Novel Drug Combo Is Promising for PD-L1-Resistant Solid Cancers ...
oncnursingnews4 天
Katie Goodman, RN, BSN, CCRP
Novel Drug Combo Is Promising for PD-L1-Resistant Solid Cancers ...
oncnursingnews5 天
Cancer Prevention Foundation
Novel Drug Combo Is Promising for PD-L1-Resistant Solid Cancers ...
oncnursingnews5 天
Dorothy N. Pierce
Novel Drug Combo Is Promising for PD-L1-Resistant Solid Cancers ...
oncnursingnews6 天
Donna L. Berry, PhD, RN, AOCN, FAAN
Novel Drug Combo Is Promising for PD-L1-Resistant Solid Cancers ...